利用长效注射剂预防艾滋病毒

IF 4 4区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases Pub Date : 2022-01-01 DOI:10.17925/id.2022.1.1.31

E. Egelund, J. Huston

{"title":"利用长效注射剂预防艾滋病毒","authors":"E. Egelund, J. Huston","doi":"10.17925/id.2022.1.1.31","DOIUrl":null,"url":null,"abstract":"Pre-exposure prophylaxis (PrEP) is an essential component in ending the HIV pandemic. Unfortunately, PrEP uptake has not been optimal to date. This is due to various reasons, one of which is adherence. Long-acting injectables may help to overcome this barrier. This brief review discusses the long-acting injectables currently in use for PrEP (cabotegravir) and HIV treatment (cabotegravir and lenacapavir), as well as those currently undergoing clinical trials. Other promising agents are being studied, including islatravir and broadly neutralizing monoclonal antibodies. Furthermore, agents currently used for HIV treatment will likely be evaluated in preclinical and clinical studies for their use as PrEP agents.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"1 1","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV Prevention Utilizing Long-acting Injectables\",\"authors\":\"E. Egelund, J. Huston\",\"doi\":\"10.17925/id.2022.1.1.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pre-exposure prophylaxis (PrEP) is an essential component in ending the HIV pandemic. Unfortunately, PrEP uptake has not been optimal to date. This is due to various reasons, one of which is adherence. Long-acting injectables may help to overcome this barrier. This brief review discusses the long-acting injectables currently in use for PrEP (cabotegravir) and HIV treatment (cabotegravir and lenacapavir), as well as those currently undergoing clinical trials. Other promising agents are being studied, including islatravir and broadly neutralizing monoclonal antibodies. Furthermore, agents currently used for HIV treatment will likely be evaluated in preclinical and clinical studies for their use as PrEP agents.\",\"PeriodicalId\":13671,\"journal\":{\"name\":\"Infectious Diseases\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17925/id.2022.1.1.31\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17925/id.2022.1.1.31","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

暴露前预防是结束艾滋病毒大流行的一个重要组成部分。不幸的是，到目前为止，PrEP的使用还不是最佳的。这是由多种原因造成的，其中之一就是坚持。长效注射剂可能有助于克服这一障碍。这篇简短的综述讨论了目前用于PrEP(卡博特韦)和HIV治疗(卡博特韦和来那卡帕韦)的长效注射剂，以及目前正在进行临床试验的长效注射剂。其他有前途的药物正在研究中，包括islatravir和广泛中和的单克隆抗体。此外，目前用于艾滋病毒治疗的药物可能会在临床前和临床研究中评估其作为PrEP药物的用途。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

HIV Prevention Utilizing Long-acting Injectables

Pre-exposure prophylaxis (PrEP) is an essential component in ending the HIV pandemic. Unfortunately, PrEP uptake has not been optimal to date. This is due to various reasons, one of which is adherence. Long-acting injectables may help to overcome this barrier. This brief review discusses the long-acting injectables currently in use for PrEP (cabotegravir) and HIV treatment (cabotegravir and lenacapavir), as well as those currently undergoing clinical trials. Other promising agents are being studied, including islatravir and broadly neutralizing monoclonal antibodies. Furthermore, agents currently used for HIV treatment will likely be evaluated in preclinical and clinical studies for their use as PrEP agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Infectious Diseases INFECTIOUS DISEASES-

CiteScore

8.20

自引率

1.70%

发文量

审稿时长

8 weeks

期刊介绍： Infectious Diseases (formerly Scandinavian Journal of Infectious Diseases) is a peer-reviewed journal publishing articles on all aspects of human infection, including pathogenesis, diagnosis, and treatment of infectious diseases, and also on medical microbiology and epidemiology